Transitioning sildenafil to taladafil in PAH patients is safe

作者
Fabienne Gonçalves,Ana Gomes,Célia Cruz,Inês Furtado,Margarida Vicente,Luísa Carvalho,Mário Santos,Abílio Reis
标识
DOI:10.1183/13993003.congress-2015.pa3781
摘要

Background: Phosphodiesterase type-5 inhibitors (iPDE5) are one of the mainstays of Pulmonary Arterial Hypertension (PAH) treatment. Tadalafil is an alternative to sildenafil with the advantage of a less frequent dosing (once instead of 3-times daily). Aim: To examine the feasibility of transitioning PAH patients from sildenafil to taladafil. Methods: We studied twenty clinically stable PAH outpatients from a single pulmonary vascular disease centre receiving sildenafil that were transitioned to tadalafil. We compared validated biochemical and functional capacity measures from the last visit under sildenafil and last follow-up visit under taladafil. Results: Patients had a mean age of 48±18 years and 75% were female. No significant differences were found between the sildenafil and taladafil evaluations. The proportion of patients at NYHA functional class 1 or 2 (65% vs 60%; p=0.16) was similar, as was the Borg class (0.5±1.1 vs 0.5±1.0; p=1.00) and 6-minute walking distance (393±168 vs 368±199 m; p=0.31). Similarly, NT-pro-BNP was stable between evaluations (590 [247-1929] vs 496 [310-2393] ng/mL; p=0.32). The median time between evaluations was 6 [4-7] months. One patient reported lower limb myalgia and had to suspend tadalafil. No other significant adverse effects were reported. Conclusions: Transitioning from sildenafil to taladafil was feasible as it was not associated with clinical worsening of PAH patients. Tadalafil was well tolerated in all patients but one, who developed myalgia that prevented treatment continuation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Alright发布了新的文献求助10
刚刚
1秒前
svg001发布了新的文献求助10
1秒前
3秒前
123完成签到,获得积分10
3秒前
yiwannian完成签到,获得积分10
3秒前
Derek发布了新的文献求助10
4秒前
科研通AI6.2的应助被Xin采纳,获得10
4秒前
kkk关闭了kkk的文献求助
4秒前
qqq完成签到 ,获得积分10
4秒前
syvshc的应助被NoMigraine采纳,获得10
4秒前
sasakiki发布了新的文献求助10
4秒前
5秒前
6秒前
miaomiao1132关注了科研通微信公众号
6秒前
ACY完成签到,获得积分10
7秒前
lucia完成签到,获得积分10
7秒前
阔达忆雪完成签到 ,获得积分10
7秒前
查找文献中完成签到,获得积分10
7秒前
myx完成签到,获得积分10
8秒前
8秒前
xnyscmbs发布了新的文献求助30
8秒前
唯念净月完成签到 ,获得积分10
9秒前
9秒前
科研通AI6.2的应助被17826539164采纳,获得10
9秒前
10秒前
10秒前
YYY完成签到 ,获得积分10
10秒前
10秒前
huang发布了新的文献求助10
10秒前
10秒前
思源的应助被YOUYOURS采纳,获得10
12秒前
香蕉觅云的应助被杨媛采纳,获得10
12秒前
周一发布了新的文献求助10
12秒前
桃汁发布了新的文献求助10
13秒前
科研通AI65的应助被LFY采纳,获得10
13秒前
多喝水呀完成签到 ,获得积分10
15秒前
悦耳的城发布了新的文献求助10
15秒前
RENZHIJIA完成签到,获得积分10
16秒前
酷波er的应助被nature大牛采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250